최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Annals of laboratory medicine, v.38 no.5, 2018년, pp.413 - 419
Lim, Hyeon-Ho (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .) , Li, Shuhua (Department of Nephrology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China .) , An, Gyu-Dae (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .) , Woo, Kwang-Sook (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .) , Kim, Kyeong-Hee (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .) , Kim, Jeong-Man (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .) , Kim, Moo-Hyun (Department of Cardiology, Dong-A University College of Medicine, Busan, Korea .) , Han, Jin-Yeong (Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea .)
BackgroundClopidogrel is one of the most commonly used anti-platelet agents in cardiovascular diseases. We analyzed the relationship between the platelet function analyzer (PFA)-200 P2Y (INNOVANCE PFA-200 System, Siemens Healthcare, Germany) results and occurrence of major adverse cardiac events (MA...
1 Kim KM Health insurance review & assessment service, healthcare bigdata hub Updated on Apr 2016 http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do
2 Stoll G Kleinschnitz C Nieswandt B Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment Blood 2008 112 3555 3562 18676880
3 Hollopeter G Jantzen HM Vincent D Li G England L Ramakrishnan V Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001 409 202 207 11196645
4 Anderson JL Adams CD Antman EM Bridges CR Califf RM Casey DE Jr 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2011 123 e426 e579 21444888
5 European Association for Percutaneous Cardiovascular Interventions (EAPCI) Wijns W Kolh P Danchin N Di Mario C Falk V Guidelines on myocardial revascularization: Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 2010 31 2501 2555 20802248
6 Gurbel PA Bliden KP Hiatt BL O'Connor CM Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 2003 107 2908 2913 12796140
7 Järemo P Lindahl TL Fransson SG Richter A Individual variations of platelet inhibition after loading doses of clopidogrel J Intern Med 2002 252 233 238 12270003
8 Price MJ Coleman JL Steinhubl SR Wong GB Cannon CP Teirstein PS Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers Am J Cardiol 2006 98 681 684 16923461
9 Angiolillo DJ Fernandez-Ortiz A Bernardo E Alfonso F Macaya C Bass TA Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 2007 49 1505 1516 17418288
10 Matetzky S Shenkman B Guetta V Shechter M Beinart R Goldenberg I Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 2004 109 3171 3175 15184279
11 Renda G Zurro M Malatesta G Ruggieri B De Caterina R Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance Haematologica 2010 95 2095 2101 21123440
12 Lordkipanidzé M Pharand C Schampaert E Turgeon J Palisaitis DA Diodati JG A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 2007 28 1702 1708 17569678
13 Koessler J Kobsar AL Rajkovic MS Schafer A Flierl U Pfoertsch S The new INNOVANCE PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition Platelets 2011 22 20 27 20873965
14 Choi JL Li S Han JY Platelet function tests: a review of progresses in clinical application Biomed Res Int 2014 2014 456569 24895576
15 Tsantes A Ikonomidis I Papadakis I Kottaridi C Tsante A Kalamara E Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance Platelets 2012 23 481 489 22646492
16 Angiolillo DJ Fernandez-Ortiz A Bernardo E Ramírez C Sabaté M Jimenez-Quevedo P Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 2005 54 2430 2435 16046311
17 Soffer D Moussa I Harjai KJ Boura JA Dixon SR Grines CL Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003 59 21 25 12720236
18 Angiolillo DJ Fernández-Ortiz A Bernardo E Barrera Ramírez C Sabaté M Fernandez C Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004 16 169 174 15152138
19 Angiolillo DJ Bernardo E Ramírez C Costa MA Sabaté M Jimenez-Quevedo P Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 2006 48 298 304 16843179
20 Taubert D Kastrati A Harlfinger S Gorchakova O Lazar A von Beckerath N Pharmacokinetics of clopidogrel after administration of a high loading dose Thromb Haemost 2004 92 311 316 15269827
21 Lau WC Waskell LA Watkins PB Neer CJ Horowitz K Hopp AS Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 2003 107 32 37 12515739
22 Neubauer H Günesdogan B Hanefeld C Spiecker M Mügge A Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study Eur Heart J 2003 24 1744 1749 14522569
23 Angiolillo DJ Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol 2007 50 296 298 17659195
24 Go AS Chertow GM Fan D McCulloch CE Hsu C Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 2004 351 1296 1305 15385656
25 Shlipak MG Fried LF Crump C Bleyer AJ Manolio TA Tracy RP Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency Circulation 2003 107 87 92 12515748
26 London GM Guérin AP Marchais SJ Métivier F Pannier B Adda H Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality Nephrol Dial Transplant 2003 18 1731 1740 12937218
27 Muntner P Hamm LL Kusek JW Chen J Whelton PK He J The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 2004 140 9 17 14706967
28 Kip KE Hollabaugh K Marroquin OC Williams DO The problem with composite end points in cardiovascular studies J Am Coll Cardiol 2008 51 701 707 18279733
29 Angiolillo DJ Fernandez-Ortiz A Bernardo E Ramírez C Cavallari U Trabetti E Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 2006 26 1895 1900 16645157
30 Beitelshees AL Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006 26 1681 1683 16857956
31 Hulot JS Bura A Villard E Azizi M Remones V Goyenvalle C Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 2006 108 2244 2247 16772608
32 Li S Choi JL Guo LZ Goh RY Kim BR Woo KS Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test Ann Lab Med 2016 36 42 48 26522758
33 Trenk D Hochholzer W Fromm MF Chialda LE Pahl A Valina CM Cytochrome P450 2C19 681G > A polymorphism and high on clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 2008 51 1925 1934 18482659
34 Collet JP Hulot JS Pena A Villard E Esteve JB Silvain J Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 2009 373 309 317 19108880
35 Simon T Verstuyft C Mary-Krause M Quteineh L Drouet E Méneveau N Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 2009 360 363 375 19106083
※ AI-Helper는 부적절한 답변을 할 수 있습니다.